ClinicalTrials.gg
RecruitingNCT06528301Updated Oct 15, 2026

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

A Phase 1 interventional study of UB-VV111 and rapamycin in Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL) and Lymphoma, Large B-Cell, Diffuse (DLBCL), sponsored by Umoja Biopharma. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Umoja Biopharma · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Oct 15, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
106
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Planned enrollment
75th of 380
106 · median 37
Started
2025
with 17 others
Phase 1
161 of 398
34 open now
Primary completion
2029-03
later than 123 of 156 live
Registered
358th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 75th largest by planned enrollment of the 380 interventional ones that give a count, is one of 18 that started in 2025, is one of 161 in phase 1, reaches primary completion later than 123 of the 156 other live ones, and was the 358th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).

03

Conditions studied

  • Lymphoma, B-Cell
  • Lymphoma, Non-Hodgkin (NHL)
  • Lymphoma, Large B-Cell, Diffuse (DLBCL)
  • Chronic Lymphocytic Leukemia (CLL)

Keywords

  • CAR T
  • CD19
  • chimeric antigen receptor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years or older
  2. Provides voluntary written
  3. large B-cell lymphoma (LBCL) or chronic lymphocytic leukemia (CLL)
  4. according to Lugano 2014 criteria (LBCL) or iwCLL 2018 (CLL).
  5. No serious concomitant diseases or active/uncontrolled infections
  6. (ECOG) performance status of 0 or 1
  7. Adequate organ function
  8. Patients who have previously received CD19-directed therapy must have confirming CD19 expression following completion of prior CD19-directed therapy.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding
  2. Current isolated central nervous system (CNS) involvement
  3. Prior bone marrow transplant, gene therapy, or adoptive cell transfer (exceptions include tumor-infiltrating lymphocytes and CAR T cells)
  4. History of or active (HIV)
  5. Active or C
  6. Systemic immunodeficiency diseases, except for well-controlled Type I diabetes or thyroid disease
  7. Ongoing CNS disease that would preclude neurologic assessment
  8. Uncontrolled angina or other acute heart disease
  9. Currently receiving treatment in another interventional clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
106 participants (estimated)

Study arms

  • Experimental
    UB-VV111

    A single dose of UB-VV111 will be administered.

    Genetic: UB-VV111

  • Experimental
    UB-VV111 + rapamycin

    A single dose of UB-VV111 will be administered followed by treatment with rapamycin.

    Genetic: UB-VV111 · Drug: rapamycin

Interventions

  • GeneticUB-VV111

    UB-VV111 is a gene therapy that generates CD19 CAR T cells in the body.

  • Rapamycin is an FDA-approved drug.

    Also known as: Rapamune, sirolimus

06

What researchers measure

Primary outcomes

  1. Percentage of participants with common adverse events (AEs)

    Percentage of participants with commonly reported AEs overall and by severity

    Time frame: Up to 2 years after UB-VV111 administration

Secondary outcomes

  1. Overall response rate (ORR)

    Percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR)

    Time frame: Up to 2 years after UB-VV111 administration

07

Study locations

9 of 9 sites recruiting
  • City of Hope
    Duarte, California 91010, United States
    Recruiting
    • Tanya Siddiqi, MD · Contacttsiddiqi@coh.org · 626-218-2405
    • Tanya Siddiqi, MD · Principal investigator
  • The David and Etta Jonas Center for Cellular Therapy
    Chicago, Illinois 60637, United States
    Recruiting
  • START Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • Washington University School of Medicine/Siteman Cancer Center
    St Louis, Missouri 63110, United States
    Recruiting
    • Yalda Karamlou · Contactyalda@wustl.edu · 314-273-3776
    • Zachary Crees, MD · Principal investigator
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-6814, United States
    Recruiting
    • Brooke Tridle, MHA · Contactbrtridle@unmc.edu · 402-559-5101
    • Matthew Lunning, D.O. F.A.C.P. · Principal investigator
  • University of Cincinnatti Medical Center
    Cincinnati, Ohio 45219, United States
    Recruiting
    • Hani Alrefai, MBBCh, MS, PhD · Contactalrefahd@ucmail.uc.edu · 513-584-8438
    • Zulfa Omer, MD · Principal investigator
  • Fred Hutch Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
    • Shelby Colden · Contactscolden2@fredhutch.org · 206-667-5134
    • Ajay Gopal, MD/FACP · Principal investigator
  • Royal North Shore Hospital
    Saint Leonards, New South Wales 2065, Australia
    Recruiting
    • Cameron Turtle, MBBS, PhD · Contact+61299264377
    • Cameron Turtle, MBBS, PhD · Principal investigator
  • St. Vincent's Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2029, 48 months after the start.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 48 months is close to that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Mar 10, 2025
Primary completionEst.
Mar 2029
CompletionEst.
Mar 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. City of Hope is now Recruiting
Show 2 added (2 United States)
  • START Midwest · Grand Rapids, United States
  • University of Cincinnatti Medical Center · Cincinnati, United States
Show 1 removed
  • University of Cincinnatti Medical Center · Cincinnatti, United States
across 2 updates, Oct 7, 2026 – Oct 15, 2026
Show all 2 updates
  1. Oct 15, 2026
    City of Hope is now Recruiting
  2. Oct 7, 2026
    2 sites added, 1 site removed
    Show 2 added (2 United States)
    • START Midwest · Grand Rapids, United States
    • University of Cincinnatti Medical Center · Cincinnati, United States
    Show 1 removed
    • University of Cincinnatti Medical Center · Cincinnatti, United States
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06528301
Lead sponsor
Umoja Biopharma
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Mar 10, 2025
Primary completion
Mar 2029 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Luke Walker, MD
Contact
luke.walker@umoja-biopharma.com
206-227-5056
Luke Walker, MD
study director · Umoja Biopharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion